SV

Street Verdict

Analyst Scorecard

HCG · NSE

Healthcare Global Enterprises Limited

₹624.95

+1.63% (+₹10.05)

Prev. close

₹614.9

Volume

81,314

Delivery %

51.9%

As of

20 Nov 2026

Price history

₹624.95-₹88.7 (-12.43%) · 3M
18 Aug 2026 → 20 Nov 2026
55060065070018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

3 analyst stances · last 90 days · one per analyst

Trackable

3 · 3 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (3)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Healthcare Global Enterprises Limited

HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services, including patient care, psychological support, nutrition, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, yoga therapy, bone marrow transplant, organ-specific oncology, radiation oncology, liver transplantation, radiology and imaging, clinical laboratory, day care chemotherapy center, home health care, preventive and psycho oncology, translational and nuclear medicine, oncodermatology, paediatric and gynaecologic oncology, anaesthesiology, and orthopaedic oncology. In addition, the company offers gastrointestinal and thoracic oncology, breast surgical oncology, and pain and palliative services. Further, it operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care; and provides oncology diagnostics services, including biomarkers, translational research, and clinical research services under the Triesta Sciences brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.

Details

Sector

Healthcare

Industry

Medical Care Facilities

CEO

Dr. Manish Mattoo

Headquarters

Bengaluru

Employees

6,761

Key stats

Market cap

₹9,199.26 Cr

P/E ratio (TTM)

405.4

Dividend yield

0.00%

EPS (TTM)

₹1.52

Beta (1Y · daily vs NIFTY 50)

0.69

Beta (5Y · monthly vs NIFTY 50)

0.38

Shares float

5.95 Cr

EPS · quarter ended Jun 2026

₹0.92

Financial Performance

01 · Financials

-2000 Cr0 Cr2000 Cr4000 Cr₹-20%-10%0%10%FY21FY22FY23FY24FY25FY26
RevenueNet incomeNet income ÷ revenue

EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.

02 · Earnings Per Share (EPS)

-20-10010₹FY21FY22FY23FY24FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-20%0%20%40%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0×0.5×1×1.5×2×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,013.44 Cr₹1,397.79 Cr₹1,694.44 Cr₹1,912.12 Cr₹2,222.85 Cr₹2,545.41 Cr
EBITDA
₹50.09 Cr₹345.26 Cr₹302.75 Cr₹350.43 Cr——
₹-193.46 Cr₹53.73 Cr₹29.34 Cr₹48.14 Cr₹44.41 Cr₹13.76 Cr
Diluted EPS
₹-17.02₹3.97₹2.1₹3.43₹3.14₹0.96

EBITDA has filed figures for only some of the years shown — the missing years are left blank rather than estimated.

EBITDA for Mar 2021 could not be checked against the company's own annual report: this page shows ₹50.09 Cr while the annual report gives ₹143.54 Cr (186.6% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹179.16 Cr) is left blank here too, rather than shown from only one of the two sources.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹2,031.00 Cr₹2,218.00 Cr₹2,311.00 Cr₹2,701.00 Cr₹3,540.00 Cr₹3,920.00 Cr
—₹914.68 Cr₹901.20 Cr₹1,274.36 Cr₹1,837.22 Cr₹1,735.35 Cr
Stockholders' equity
₹697.00 Cr₹870.00 Cr₹860.00 Cr₹825.00 Cr₹922.00 Cr₹1,332.00 Cr

Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹121.00 Cr₹220.00 Cr₹252.00 Cr₹285.00 Cr₹317.00 Cr₹347.00 Cr
Investing cash flow
₹-171.10 Cr₹124.58 Cr₹-133.02 Cr₹-225.73 Cr₹-487.75 Cr₹-177.47 Cr
₹112.00 Cr₹-155.00 Cr₹-140.00 Cr₹-64.00 Cr₹-42.00 Cr₹241.00 Cr
Capital expenditure
₹-35.00 Cr₹-71.00 Cr₹-133.00 Cr₹-186.00 Cr₹-209.00 Cr₹-292.00 Cr
End cash position
₹2.86 Cr₹192.69 Cr₹171.18 Cr₹166.01 Cr₹-47.05 Cr₹363.23 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24–Dec 24(2Q)Mar 25Jun 25Sep 25Dec 25Mar 26–Jun 26(3Q)
Promoter68.41%71.02%71.44%71.43%71.42%71.39%71.38%71.37%71.35%71.30%71.29%71.28%71.25%71.23%71.22%62.46%63.78%63.77%64.21%
Public31.60%28.99%28.56%28.57%28.58%28.61%28.62%28.63%28.65%28.70%28.71%28.72%28.75%28.77%28.78%37.54%36.22%36.23%35.79%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Healthcare Global Enterprises Limited₹9,316.46 Cr₹621.35402.66.991.0%1.30+14.6%-18.5%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

2 indices

HCG

HealthCare Global Enterprises Limited Q2 Revenue Rises 16%

Multibagg AI · 13 days ago

HCG

Why HCG Fell Even As Sales Rose

HealthCare Global Enterprises' shares dropped to about ₹600, a 20.5% loss over the past year despite revenue rising to ₹7.34 billion in Q2 2027. The decline reflects shrinking net margins, which fell to 0.7% as net income dropped, challenging earlier expectations of strong margin expansion from its oncology and KKR‑backed growth plans.